Rituximab ITP Aiha denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for rituximab itp aiha are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Rituximab (ITP/AIHA) as Not FDA-Approved

Rituximab's FDA approval covers specific labeled indications, and ITP (immune thrombocytopenia) and AIHA (autoimmune hemolytic anemia) are not among them — making its use in these conditions off-label. Humana may issue a "not FDA-approved" denial on this basis. However, off-label use of an FDA-approved drug is a standard and accepted part of medical practice, particularly in hematology, and plans are generally required under federal and state law to consider coverage when the use is supported by recognized medical evidence.

## Why This Denial Is Appealable

Being off-label does not mean being uncovered. Under ERISA-governed plans and many ACA-compliant plans, off-label drug uses must be covered when supported by recognized medical compendia or authoritative clinical evidence. Your appeal should focus on demonstrating that rituximab for ITP or AIHA is recognized by the relevant hematology specialty organizations and is reflected in the medical literature, and that your prescribing hematologist has determined it is the appropriate treatment for your individual case. Humana's own policy may have an evidence-based coverage pathway that does not require FDA approval for this indication.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your denial letter. ERISA §503 and ACA §2719 require Humana to conduct a full-and-fair review with appropriate clinical expertise and issue a written decision with specific reasons.
• External review: If denied internally, you have approximately four months from the internal-appeal decision under federal rules to request IRO external review. This is a particularly strong pathway for off-label denials — independent reviewers evaluate the medical evidence directly.
• Expedited review: Request if the patient has active significant bleeding or other urgent circumstances.

## Documentation to Gather

• Prescriber letter: The treating hematologist should state that the use of rituximab for this specific indication is consistent with accepted medical practice and explain the clinical basis for that position.
• Humana's coverage policy: Obtain the current version — some Humana policies include a coverage pathway for rituximab in ITP/AIHA despite the off-label status. If so, map your case directly to those criteria.
• Diagnosis confirmation: Hematology notes, bone marrow or lab findings, and relevant specialist workup confirming the ITP or AIHA diagnosis.
• Prior-treatment history: Documentation of therapies previously tried and their outcomes, establishing that rituximab is not a first-line choice.

## Criteria-Mapping Structure

In a two-column table, list Humana's coverage criteria or exclusion language on the left. On the right, address each criterion with chart evidence and the prescriber's clinical judgment. For the off-label classification specifically, include a row where the prescriber addresses whether the use is consistent with accepted standards of medical practice — this is the legal standard most plans must apply.